Caris Life Sciences(CAI.US)

Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer

Caris Life Sciences Inc. has published a study in Nature’s npj Breast Cancer journal on resistance mechanisms to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. Analyzing data from 2,799 patients, the study identified ERBB2 (HER2) and ABCC1 as key predictors of survival. Higher ERBB2 expression linked to better outcomes, while higher ABCC1 correlated with worse outcomes. The research also noted increased ABCC1 and mutations in ERBB2, NFE2L2, KEAP1, and TOP1 in post-treatment samples, indicating potential acquired resistance pathways. The study's findings are already published.

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

Mabtech and Sai Life Sciences have announced a strategic collaboration to enhance immunology research using the EYRA platform at Sai's Boston site. This partnership will provide advanced immunology assay services, including multiplex cytokine workflows, to biopharma and biotech companies. The EYRA platform offers efficient immune profiling capabilities, integrating advanced technology into Sai's discovery operations. Key elements of the collaboration include joint service delivery, co-branded demonstrations, and shared thought leadership, aimed at accelerating the development of immunology and immuno-oncology programs.

Caris Life Sciences | 8-K: FY2025 Q4 Revenue: USD 281 M

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth | NTRA Stock News

Natera, Inc. (NASDAQ: NTRA) announced strong preliminary financial results for Q4 and full year 2025, with revenues expected to reach approximately $660 million for Q4, a 39% increase from Q4 2024, and $2.3 billion for the full year, a 35% increase from 2024. The company processed about 923,600 tests in Q4, a 17% increase year-over-year. CEO Steve Chapman highlighted record growth in oncology and women's health, and additional updates will be presented at the J.P. Morgan Healthcare Conference on January 13, 2026. Full financial results will be released in February 2026.

Caris Life Sciences, Inc. (NASDAQ:CAI) Has Found A Path To Profitability

Caris Life Sciences, Inc. (NASDAQ:CAI) is nearing profitability, with analysts predicting a final loss in 2025 and positive profits of US$46m in 2026. The company, which specializes in molecular profiling services, reported a loss of US$378m last year and US$682m in the latest trailing twelve months. Analysts expect a growth rate of 66% year-on-year to reach breakeven. However, the company has a high debt level at 79% of equity, increasing investment risk. Further research is recommended for a deeper understanding of the company's valuation and management team.